Market Place
Sourcing Support
Japan`s Teijin inks $230 M deal with Novartis for kidney diseases treatment
08 Mar 2023 //
BIOSPECTRUM ASIA
Teijin and Axcelead to establish drug discovery research JV
21 Feb 2023 //
INDIAN PHARMA POST
Teijin Pharma Receives Approval Japan for Abaloparatide Acetate for Osteoporosis
05 Sep 2022 //
PRESS RELEASE
Iktos, Teijin Pharma to Co-Develop New Technology for SMD Discovery
05 Apr 2022 //
BUSINESSWIRE
Teijin Receives Additional Approval in Japan for Merz`s Xeomin® Botulinum Toxin
23 Jun 2021 //
BUSINESSWIRE
Teijin receives additional approval in Japan for botulinum toxin type A Xeomin
22 Jun 2021 //
BUSINESSWIRE
Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma
02 Apr 2021 //
PRESS RELEASE
Takeda sells Japan’s non-core products portfolio to Teijin Pharma
01 Apr 2021 //
PHARMACEUTICAL-TECHNOLOGY
Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma
31 Mar 2021 //
TAKEDA
Japan`s Takeda sells four diabetes products to Teijin Pharma for $1.25 billion
27 Feb 2021 //
REUTERS
Takeda transfers assets of select diabetes products to Teijin Pharma
25 Feb 2021 //
BIOPECTRUMASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.